Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

PubWeight™: 5.08‹?› | Rank: Top 1%

🔗 View Article (PMID 28304224)

Published in N Engl J Med on March 17, 2017

Authors

Marc S Sabatine1, Robert P Giugliano1, Anthony C Keech1, Narimon Honarpour1, Stephen D Wiviott1, Sabina A Murphy1, Julia F Kuder1, Huei Wang1, Thomas Liu1, Scott M Wasserman1, Peter S Sever1, Terje R Pedersen1, FOURIER Steering Committee and Investigators

Author Affiliations

1: From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (M.S.S., R.P.G., S.D.W., S.A.M., J.F.K.); Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (A.C.K.); Amgen, Thousand Oaks, CA (N.H., H.W., T.L., S.M.W.); International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London (P.S.S.); and Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo (T.R.P.).

Associated clinical trials:

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) | NCT01764633

Articles citing this

Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circ Res (2017) 1.06

Evolocumab in Patients with Cardiovascular Disease. N Engl J Med (2017) 0.97

Evolocumab in Patients with Cardiovascular Disease. N Engl J Med (2017) 0.97

Evolocumab in Patients with Cardiovascular Disease. N Engl J Med (2017) 0.95

Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol (2017) 0.90

Diversity and inclusion in genomic research: why the uneven progress? J Community Genet (2017) 0.79

Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat Struct Mol Biol (2017) 0.78

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? Nat Rev Nephrol (2017) 0.76

Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering. Nat Rev Cardiol (2017) 0.75

Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. Nat Rev Cardiol (2017) 0.75

The Role of Emerging Risk Factors in Cardiovascular Outcomes. Curr Atheroscler Rep (2017) 0.75

PCSK9 Inhibition to Reduce Cardiovascular Events. N Engl J Med (2017) 0.75

Atherosclerosis: PCSK9 inhibition reduces cardiovascular events in high-risk patients. Nat Rev Cardiol (2017) 0.75

Response letter: Management of statin-induced myopathies: Much demands and still (almost) empty hands! J Cachexia Sarcopenia Muscle (2017) 0.75

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. Int J Clin Pract (2017) 0.75

Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis (2017) 0.75

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. J Lipid Res (2017) 0.75

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One (2017) 0.75

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. Vasc Health Risk Manag (2017) 0.75

Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia. Drugs (2017) 0.75

Cholesterol Management in the Era of PCSK9 Inhibitors. Curr Cardiol Rep (2017) 0.75

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial. J Community Hosp Intern Med Perspect (2017) 0.75

Coronary Artery Calcium Scoring in Current Clinical Practice: How to Define Its Value? Curr Treat Options Cardiovasc Med (2017) 0.75

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol (2017) 0.75

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Curr Atheroscler Rep (2017) 0.75

Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke. Drug Saf (2017) 0.75

[Genetic testing in polygenic diseases : Atrial fibrillation, arterial hypertension and coronary artery disease]. Herz (2017) 0.75

Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thorac Dis (2017) 0.75

Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol. Nat Struct Mol Biol (2017) 0.75